PE20211585A1 - Agente profilactico o terapeutico para atrofia muscular espinal - Google Patents
Agente profilactico o terapeutico para atrofia muscular espinalInfo
- Publication number
- PE20211585A1 PE20211585A1 PE2020002186A PE2020002186A PE20211585A1 PE 20211585 A1 PE20211585 A1 PE 20211585A1 PE 2020002186 A PE2020002186 A PE 2020002186A PE 2020002186 A PE2020002186 A PE 2020002186A PE 20211585 A1 PE20211585 A1 PE 20211585A1
- Authority
- PE
- Peru
- Prior art keywords
- aliphatic heterocycle
- optionally substituted
- muscular atrophy
- spinal muscular
- hydrogen atom
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61C—DENTISTRY; APPARATUS OR METHODS FOR ORAL OR DENTAL HYGIENE
- A61C8/00—Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereon; Dental implants; Implanting tools
- A61C8/0093—Features of implants not otherwise provided for
- A61C8/0096—Implants for use in orthodontic treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Zoology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
La presente invencion se refiere a compuestos representados por la formula 1 o una sal de estos, en donde: W1, W2 y W3 se seleccionan cada uno independientemente del grupo que consiste en C-R2, C-R3, C-Rc y C-Rd, y se definen mediante uno de los siguientes (i) a (iv): (i) cuando W3 es C-R2, entonces W1 es C-R3, W2 es C-Rc o N, y R1 es un atomo de hidrogeno; (ii) cuando W3 es C-R3, entonces W1 es C-R2, W2 es C-Rc o N, y R1 es un atomo de hidrogeno, alquilo C1-8 o alcoxi C1-8; (iii) cuando W1 es C-R2, entonces W2 es C-Rc o N, W3 es C-Rd, y R1 es un heterociclo alifatico que contiene uno o mas atomos de nitrogeno, donde el heterociclo alifatico se sustituye opcionalmente con un sustituyente no aromatico; y (iv) cuando W2 es C-R2, W1 es C-Rc, W3 es C-Rd, y R1 es un heterociclo alifatico que contiene uno o mas atomos de nitrogeno, donde el heterociclo alifatico se sustituye opcionalmente con un sustituyente no aromatico; R2 es un anillo aromatico de 6 o mas miembros opcionalmente sustituido con un sustituyente no aromatico; R3 es un heterociclo alifatico que contiene uno o mas atomos de nitrogeno, donde el heterociclo alifatico se sustituye opcionalmente con un sustituyente no aromatico; Q1 se selecciona de C-Ra y N; Q2 se selecciona de C-Rb y N; y Ra, Rb, Rc y Rd se seleccionan cada uno independientemente del grupo que consiste en un atomo de hidrogeno, halogeno, alquilo C1-8, alcoxi C1-8 y un grupo ciano. Son compuestos preferidos: (S)-6-(2,4-dimetilpiperazin-1-il)-2-(4,6-dimetilpirazolo[1,5-a]pirazin-2-il)quinazolin-4(3H)-ona; 2-(4,6-dimetilpirazolo[1,5-a]pirazin-2-il)-6-(4-metilpiperazin-1-il)quinazolin-4(3H)-ona, entre otros. Tambien se refiere a un medicamento, un regulador de empalme, un potenciador de expresion del ARNm de SMN con funcion normal y/o proteina SMN de funcion normal, un agente profilactico de atrofia muscular espinal (SMA) asociados al compuesto de la invencion. Los compuestos de la invencion tienen utilidad como agentes profilacticos o terapeuticos para la atrofia muscular espinal, potenciando la expresion del ARNm normal del gen de supervivencia de motoneuronas 1 (SMN1) o su proteina funcional.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018122551 | 2018-06-27 | ||
PCT/JP2019/025732 WO2020004594A1 (ja) | 2018-06-27 | 2019-06-27 | 脊髄性筋萎縮症の予防または治療剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20211585A1 true PE20211585A1 (es) | 2021-08-18 |
Family
ID=68986733
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2020002186A PE20211585A1 (es) | 2018-06-27 | 2019-06-27 | Agente profilactico o terapeutico para atrofia muscular espinal |
Country Status (19)
Country | Link |
---|---|
US (1) | US20220287748A1 (es) |
EP (1) | EP3816160A4 (es) |
JP (1) | JP7427252B2 (es) |
KR (1) | KR20210025625A (es) |
CN (1) | CN112469707A (es) |
AU (2) | AU2019293757B2 (es) |
BR (1) | BR112020026637A2 (es) |
CA (1) | CA3105174A1 (es) |
CL (1) | CL2020003386A1 (es) |
CO (1) | CO2021000808A2 (es) |
CR (1) | CR20210050A (es) |
EA (1) | EA202190116A1 (es) |
IL (1) | IL279786A (es) |
JO (1) | JOP20200338A1 (es) |
MX (1) | MX2020014116A (es) |
PE (1) | PE20211585A1 (es) |
PH (1) | PH12020552263A1 (es) |
SG (1) | SG11202013088YA (es) |
WO (1) | WO2020004594A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018309187C1 (en) | 2017-08-04 | 2023-09-07 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
WO2020006018A1 (en) | 2018-06-27 | 2020-01-02 | Bristol-Myers Squibb Company | Substituted naphthyridinone compounds useful as t cell activators |
IL280213B1 (en) * | 2018-07-26 | 2024-02-01 | Domain Therapeutics | Altered quinazolinone derivatives and their use as positive allosteric modulators of MGLUR4 |
CR20220484A (es) * | 2020-02-28 | 2022-12-15 | Remix Therapeutics Inc | Amidas heterocíclicas y su uso para modular el empalme |
CA3174353A1 (en) | 2020-04-08 | 2021-10-14 | Dominic Reynolds | Compounds and methods for modulating splicing |
CA3175193A1 (en) | 2020-04-08 | 2021-10-14 | Dominic Reynolds | Compounds and methods for modulating splicing |
US20240002375A1 (en) | 2020-07-02 | 2024-01-04 | Remix Therapeutics Inc. | 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the tre |
AU2021300260A1 (en) | 2020-07-02 | 2023-02-09 | Remix Therapeutics Inc. | 5-[5-(piperidin-4-yl)thieno[3,2-c]pyrazol-2-yl]indazole derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases |
CN112028896A (zh) * | 2020-10-14 | 2020-12-04 | 奥锐特药业(天津)有限公司 | 阿卡替尼的新晶型及其制备方法 |
CA3233973A1 (en) * | 2021-10-13 | 2023-04-20 | Dominic Reynolds | Compounds and methods for modulating nucleic acid splicing |
TW202330552A (zh) * | 2021-10-13 | 2023-08-01 | 美商雷密克斯醫療公司 | 調節剪接之化合物及方法 |
TW202346305A (zh) | 2022-01-05 | 2023-12-01 | 美商雷密克斯醫療公司 | 用於調節剪切之化合物及方法 |
WO2023133217A1 (en) | 2022-01-05 | 2023-07-13 | Remix Therapeutics Inc. | 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases |
WO2023133229A2 (en) | 2022-01-05 | 2023-07-13 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1050750B (it) * | 1975-12-05 | 1981-03-20 | Erba Carlo Spa | Derivati della 3.4 di idro chinazolina |
BR0116113A (pt) * | 2000-12-12 | 2004-08-03 | Neurogen Corp | Espiro[isobenzofuran-1,4'-piperidin]-3-onas e 3h-espiroisoben-zofuran-1,4'-piperidinas |
KR20210057223A (ko) | 2009-06-17 | 2021-05-20 | 바이오젠 엠에이 인코포레이티드 | 대상에게서 smn2 스플라이싱을 조정하기 위한 조성물 및 방법 |
CA2771532C (en) * | 2009-08-17 | 2021-03-23 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
CN102666540A (zh) * | 2009-10-13 | 2012-09-12 | Msd欧斯股份有限公司 | 用于治疗乙酰胆碱受体相关疾病的稠合吖嗪衍生物 |
CN106619647A (zh) * | 2011-02-23 | 2017-05-10 | 因特利凯有限责任公司 | 激酶抑制剂的组合及其用途 |
US8710064B2 (en) | 2011-10-20 | 2014-04-29 | China Medical University | 2-aryl-4-quinazolinones and their pharmaceutical compositions |
WO2013071264A1 (en) * | 2011-11-11 | 2013-05-16 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
CA2862084C (en) | 2012-01-26 | 2021-05-11 | Ptc Therapeutics, Inc. | 1h-isochromen-1-one derivatives and compositions thereof for treating spinal muscular atrophy |
BR112014019750B1 (pt) | 2012-02-10 | 2020-03-03 | F. Hoffmann-La Roche Ag. | Composto, composição farmacêutica e seus usos |
WO2014151147A1 (en) | 2013-03-15 | 2014-09-25 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
CN108026046B (zh) * | 2015-07-22 | 2021-12-21 | 亚瑞克西斯制药公司 | 取代的喹唑啉化合物及其作为g12c突变体kras、hras和/或nras蛋白质的抑制剂的用途 |
JP6869947B2 (ja) * | 2015-07-22 | 2021-05-12 | アラクセス ファーマ エルエルシー | 置換キナゾリン化合物ならびにそのg12c変異kras、hrasおよび/またはnrasタンパク質の阻害剤としての使用 |
CA3002494C (en) | 2015-11-12 | 2021-01-12 | F. Hoffmann-La Roche Ag | Compositions for treating spinal muscular atrophy |
EP3573970A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
JP6868410B2 (ja) | 2017-02-03 | 2021-05-12 | エスアイアイ・プリンテック株式会社 | 液体噴射ヘッドチップ、液体噴射ヘッドおよび液体噴射装置 |
-
2019
- 2019-06-27 BR BR112020026637-0A patent/BR112020026637A2/pt unknown
- 2019-06-27 CA CA3105174A patent/CA3105174A1/en active Pending
- 2019-06-27 JO JOP/2020/0338A patent/JOP20200338A1/ar unknown
- 2019-06-27 SG SG11202013088YA patent/SG11202013088YA/en unknown
- 2019-06-27 KR KR1020217002751A patent/KR20210025625A/ko active IP Right Grant
- 2019-06-27 US US17/255,843 patent/US20220287748A1/en active Pending
- 2019-06-27 WO PCT/JP2019/025732 patent/WO2020004594A1/ja active Application Filing
- 2019-06-27 MX MX2020014116A patent/MX2020014116A/es unknown
- 2019-06-27 AU AU2019293757A patent/AU2019293757B2/en active Active
- 2019-06-27 EP EP19827283.3A patent/EP3816160A4/en active Pending
- 2019-06-27 PE PE2020002186A patent/PE20211585A1/es unknown
- 2019-06-27 EA EA202190116A patent/EA202190116A1/ru unknown
- 2019-06-27 JP JP2020527663A patent/JP7427252B2/ja active Active
- 2019-06-27 CR CR20210050A patent/CR20210050A/es unknown
- 2019-06-27 CN CN201980048524.9A patent/CN112469707A/zh active Pending
-
2020
- 2020-12-23 PH PH12020552263A patent/PH12020552263A1/en unknown
- 2020-12-24 CL CL2020003386A patent/CL2020003386A1/es unknown
- 2020-12-27 IL IL279786A patent/IL279786A/en unknown
-
2021
- 2021-01-26 CO CONC2021/0000808A patent/CO2021000808A2/es unknown
-
2022
- 2022-12-08 AU AU2022283732A patent/AU2022283732A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
SG11202013088YA (en) | 2021-02-25 |
EA202190116A1 (ru) | 2021-08-30 |
CN112469707A (zh) | 2021-03-09 |
PH12020552263A1 (en) | 2021-06-28 |
MX2020014116A (es) | 2021-06-15 |
AU2019293757A1 (en) | 2021-02-04 |
JP7427252B2 (ja) | 2024-02-05 |
EP3816160A1 (en) | 2021-05-05 |
BR112020026637A2 (pt) | 2021-03-30 |
KR20210025625A (ko) | 2021-03-09 |
AU2019293757B2 (en) | 2022-09-15 |
CA3105174A1 (en) | 2020-01-02 |
IL279786A (en) | 2021-03-01 |
CO2021000808A2 (es) | 2021-04-30 |
JOP20200338A1 (ar) | 2020-12-24 |
JPWO2020004594A1 (ja) | 2021-07-15 |
US20220287748A1 (en) | 2022-09-15 |
CR20210050A (es) | 2021-06-10 |
EP3816160A4 (en) | 2022-03-16 |
CL2020003386A1 (es) | 2021-05-14 |
AU2022283732A1 (en) | 2023-02-02 |
WO2020004594A1 (ja) | 2020-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20211585A1 (es) | Agente profilactico o terapeutico para atrofia muscular espinal | |
PE20211411A1 (es) | Compuestos de anillo fusionado | |
PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
PE20191755A1 (es) | Derivados de pirazol como inhibidores de malt 1 | |
ES2676180T3 (es) | Terapia de combinación que comprende un inhibidor de CDK4/6 y un inhibidor de PI3K para el uso en el tratamiento de cáncer | |
PE20230249A1 (es) | Compuestos de heteroarilo biciclicos y usos de estos | |
PE20211807A1 (es) | Derivados de pirazina fusionados como inhibidores de a2a/a2b | |
DOP2022000266A (es) | 2-amino-3-cianotiofenos anulados y derivados para el tratamiento del cáncer | |
UY29301A1 (es) | Derivados amida | |
UY28157A1 (es) | Miméticos de glucocorticoides métodos para su elaboración composiciones farmacéuticas y sus usos | |
PE20210129A1 (es) | Compuestos de 4-azaindol | |
UY29198A1 (es) | Derivados sustituidos de quinazolinona y derivados sustituidos de quinazolina-2, 4-diona, composiciones conteniéndolos, procedimientos de preparación y aplicaciones | |
PE20211089A1 (es) | Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa | |
PE20120120A1 (es) | DERIVADOS DE 2H-PIRAZOLO[3,4-d]PIRIMIDINA-4,6(5H,7H)-DIONA, COMO INHIBIDORES DE PDE1 | |
PE20090054A1 (es) | Derivados de purina | |
BRPI0507945A (pt) | derivados de azabiciclo (3.1.0) hexano utilizáveis como moduladores de receptores d3 de dopamina | |
PE20051047A1 (es) | COMPUESTOS [1,2,4] TRIAZOL [4,3-b]PIRIDAZIN-3-ONA COMO MODULADORES DE RECEPTOR CANABINOIDE | |
AR080841A1 (es) | Derivados de isoxazolina sustituida; composiciones veterinarias que los comprenden y su uso en el tratamiento de parasitos en animales | |
AR041374A1 (es) | Derivados de 2-oxodihidropiridina n- sustituidos | |
PE20141110A1 (es) | Derivados heterociclicos novedosos para el tratamiento de trastornos neurologicos | |
PE20140381A1 (es) | Dispersiones solidas extruidas por fusion que contienen un agente inductor de apoptosis | |
AR062360A1 (es) | Derivados heterociclicos que modulan la actividad de la estearoil-coa-desaturasa | |
BR112022005674A2 (pt) | Derivado de anel fundido aromático substituído e composição compreendendo o mesmo, e uso do mesmo | |
PE20121471A1 (es) | Derivados de sulfonamida heterociclicos utiles como inhibidores de mek | |
PE20211388A1 (es) | Compuestos |